A Novel Target in Vitiligo: CxCL10
Time: 11:15 am
day: Day One Discovery Track AM
Details:
- Vitiligo remains an area with a significant unmet need, in particular for new targeted systemic treatments
- The IFNγ-CXCL10-CXCR3 pathway offers new and exciting opportunities for addressing the condition, with CXCL10 playing an important role in apoptosis of melanocytes, and recruitment and positioning of effector T-cells
- EB06 is a novel anti-CXCL10 monoclonal antibody that is being developed for treatment of vitiligo.
